Thiopurine Metabolism in the Era of Combotherapy.

about

Thiopurine Metabolism in the Era of Combotherapy.

Item

http://www.wikidata.org/entity/Q50691937

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Thiopurine Metabolism in the Era of Combotherapy.

@en

Thiopurine Metabolism in the Era of Combotherapy.

@nl

type

Item

label

Thiopurine Metabolism in the Era of Combotherapy.

@en

Thiopurine Metabolism in the Era of Combotherapy.

@nl

prefLabel

Thiopurine Metabolism in the Era of Combotherapy.

@en

Thiopurine Metabolism in the Era of Combotherapy.

@nl

P1476

Thiopurine Metabolism in the Era of Combotherapy.

@en

P2093

Nicolas Williet

http://www.w3.org/2001/XMLSchema#string

Xavier Roblin

http://www.w3.org/2001/XMLSchema#string

P2860

6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.

Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.

Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

P304

1496-1501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000000737

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Peyrin-Biroulet

P577

2016-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26978723

http://www.w3.org/2001/XMLSchema#string